BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• 

  Business

  Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationships with WuXi and Alibaba

  Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.

  May 24, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Sun Pharma Gets FDA Go-Ahead for Yonsa for Prostate Cancer

  Sun Pharma received approval from the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC). Sun will launch the drug in the U.S. via a licensing deal with Churchill Pharmaceuticals, the original developer of the drug.

  May 24, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Job Trends

  AstraZeneca Opens New Bay Area R&D Site With 400 Employees

  After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.

  May 24, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Johnson & Johnson Loses $21.7 Million Verdict over Talc Asbestos Cancer Link

  A Los Angeles jury sided with 68-year-old Joanne Anderson, who was diagnosed with mesothelioma allegedly linked to a Johnson & Johnson talc product. It is the second similar award regarding the product.

  May 24, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  BioMidwest

  May 25th Research Roundup: Some of the Top Research Stories of the Week

  There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

  May 24, 2018

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Bloom Science Launches from Exclusive UCLA Tech License

  San Diego-based Bloom Science launched to develop epilepsy treatments based on a new class of neuroprotective drugs. The company, whose research was published in the journal Cell today, focuses on gut bacteria involved in the anti-seizure effects of the ketogenic diet.

  May 24, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Aptinyx Eyes $80 Million IPO to Advance its NMDA Drug Programs

  A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.

  May 24, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Novo Nordisk Licenses Kidney Disease Drug from Epigen Biosciences

  Novo Nordisk licensed an experimental chronic kidney disease (CKD) and diabetic kidney disease (DKD) treatment in a deal that could be worth up to $200 million for San Diego-based Epigen Biosciences.

  May 24, 2018

   · 

  2 min read

   · 

  Alex Keown
• FDA

  AcelRx announces FDA acceptance of NDA for DSUVIA

  DSUVIA PDUFA date set for November 3, 2018

  May 24, 2018

   · 

  4 min read
• Business

  Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck

  Pan-Cancer MSI Companion Diagnostic for KEYTRUDA® (pembrolizumab) Planned for Inclusion on FoundationOne CDx™

  May 24, 2018

   · 

  6 min read